ethyl 7-(2-ethylbutoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: ethyl 7-(2-ethylbutoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylate
• 化学式: C₁₉H₂₃F₃O₄
• 分子量: 372.384
• InChiKey: KLKJZQUZKCCRQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  ethyl 7-(2-ethylbutoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylate 在 sodium acetate 、 氯 作用下， 以 溶剂黄146 为溶剂， 反应 2.0h， 生成 ethyl 6,8-dichloro-7-(2-ethylbutoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylate
  参考文献：
  名称：

  [EN] CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS
  [FR] DERIVES DE CHROMENE A TITRE D'AGENTS ANTI-INFLAMMATOIRES

  摘要：

  该发明涉及在治疗与环氧合酶-2介导的疾病相关的情况中具有效用的方法和化合物。特别感兴趣的化合物是由式(I)定义的苯并吡喃和它们的类似物。其中Z、X、R1、R2、R3和R4如规范中所述。

  公开号：

  WO2004087687A1
• 作为产物：
  描述：

  ethyl 7-hydroxy-2-(trifluoromethyl)-2H-chromene-3-carboxylate 、 2-乙基-1-丁醇 在 triphenylphosphine polystyrene 、 ethyl azodicarboxylate 作用下， 以 四氢呋喃 为溶剂， 反应 0.25h， 以92%的产率得到ethyl 7-(2-ethylbutoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylate
  参考文献：
  名称：

  [EN] CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS
  [FR] DERIVES DE CHROMENE A TITRE D'AGENTS ANTI-INFLAMMATOIRES

  摘要：

  该发明涉及在治疗与环氧合酶-2介导的疾病相关的情况中具有效用的方法和化合物。特别感兴趣的化合物是由式(I)定义的苯并吡喃和它们的类似物。其中Z、X、R1、R2、R3和R4如规范中所述。

  公开号：

  WO2004087687A1

文献信息

• [EN] CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS<br/>[FR] DERIVES DE CHROMENE A TITRE D'AGENTS ANTI-INFLAMMATOIRES
  申请人：PHARMACIA CORP

  公开号：WO2004087687A1

  公开（公告）日：2004-10-14

  The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula (I). Wherein Z, X, R1, R2, R3, and R4 are as described in the specification.

  该发明涉及在治疗与环氧合酶-2介导的疾病相关的情况中具有效用的方法和化合物。特别感兴趣的化合物是由式(I)定义的苯并吡喃和它们的类似物。其中Z、X、R1、R2、R3和R4如规范中所述。
• Benzopyran compounds useful for treating inflammatory conditions
  申请人：Carter Jeffery

  公开号：US20050148777A1

  公开（公告）日：2005-07-07

  The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula 1 Wherein Z, X, R 1 , R 2, R 3 , and R 4 are as described in the specification.

  本发明涉及与环氧合酶-2介导的疾病相关的病症治疗方法和化合物。特别感兴趣的化合物是由公式1定义的苯并吡喃和其类似物，其中Z、X、R1、R2、R3和R4如规范中所述。
• Benzopyran compounds for use in the treatment and prevention of inflammation related conditions
  申请人：Carter Jeffery

  公开号：US20050148627A1

  公开（公告）日：2005-07-07

  The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula 1 Wherein Z, X, R 1 , R 2 , R 3 , and R 4 are as described in the specification.

  本发明涉及用于治疗与环氧合酶-2介导的疾病相关的条件的方法和化合物。特别感兴趣的化合物是苯并吡喃和它们的类似物，其由公式1定义，其中Z、X、R1、R2、R3和R4如规范中所述。
• US7259266B2
  申请人：——

  公开号：US7259266B2

  公开（公告）日：2007-08-21
• The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life
  作者：Jane L. Wang、David Limburg、Matthew J. Graneto、John Springer、Joseph Rogier Bruce Hamper、Subo Liao、Jennifer L. Pawlitz、Ravi G. Kurumbail、Timothy Maziasz、John J. Talley、James R. Kiefer、Jeffery Carter

  DOI：10.1016/j.bmcl.2010.07.054

  日期：2010.12

  In this Letter, we provide the structure-activity relationships, optimization of design, testing criteria, and human half-life data for a series of selective COX-2 inhibitors. During the course of our structure-based drug design efforts, we discovered two distinct binding modes within the COX-2 active site for differently substituted members of this class. The challenge of a undesirably long human half-life for the first clinical candidate 1 t(1/2) = 360 h was addressed by multiple strategies, leading to the discovery of 29b-(S) (SC-75416) with t(1/2) = 34 h. (C) 2010 Elsevier Ltd. All rights reserved.